Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| Rapport Therapeutics, Inc. | 130,000 | reported | 02 Feb 2026 | tx 2+430,000 |
| Acumen Pharmaceuticals, Inc. | 25,000 | reported | 15 Jun 2022 | tx 2+59,000 |
| Prevail Therapeutics Inc. | 0 | reported | 22 Jan 2021 | tx 4+89,000−611,781 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 02 Feb 2026 | GRANT_AWARD | Rapport Therapeutics, Inc. | 130,000 | 0.00 USD | deriv |
| 01 Apr 2025 | GRANT_AWARD | Rapport Therapeutics, Inc. | 300,000 | 0.00 USD | deriv |
| 15 Jun 2022 | GRANT_AWARD | Acumen Pharmaceuticals, Inc. | 25,000 | 0.00 USD | deriv |
| 30 Jun 2021 | GRANT_AWARD | Acumen Pharmaceuticals, Inc. | 34,000 | 0.00 USD | deriv |
| 22 Jan 2021 | OTHER | Prevail Therapeutics Inc. | 400,342 | 0.00 USD | deriv |
| 22 Jan 2021 | OTHER | Prevail Therapeutics Inc. | 122,439 | 0.00 USD | deriv |
| 22 Jan 2021 | OTHER | Prevail Therapeutics Inc. | 89,000 | 0.00 USD | deriv |
| 19 Feb 2020 | GRANT_AWARD | Prevail Therapeutics Inc. | 89,000 | 0.00 USD | deriv |